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Summary For some applications, the success of gene therapy depends on the
efﬁciency of gene transfer into target organs, however, delivery to many tissues
is limited. Efforts have been made to improve the efﬁciency of gene transfer into
target organs such as the brain by using mannitol or vascular endothelial growth
factor (VEGF) prior to gene delivery, since these treatments have been reported to
increase vascular permeability in experimental animals. Here, we investigated the
effect of VEGF pretreatment of neonatal mice on the ability of injected lentivirus
(LV) — engineering expression of ﬁreﬂy luciferase (luc) — to enhance the transduction
of various organs, including the brain and heart. LV/luc was delivered to VEGF-
treated neonatal mice via the temporal vein. Whole-body bioluminescence imaging
(WBLI) of luciferase expression showed that VEGF pretreatment does not diminish
transgene expression over time since it remained steady for up to 12 weeks. Ex vivo
imaging of the organs and assessments of organ luciferase activity showed that VEGF
pretreatment resulted in signiﬁcantly increased luciferase expression not only in the
heart, but also in the brain, lung, and kidney. This study shows that VEGF may have
therapeutic importance to enhance the efﬁciency of viral gene delivery to the heart,
as well as to other target organs.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
∗ Corresponding author at: Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine,
-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. Tel.: +81 22 717 8062; fax: +81 22 717 8065.
E-mail address: tksato@mail.tains.tohoku.ac.jp (T. Sato).
914-5087/$ — see front matter © 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jjcc.2009.05.010
i
p
i
h
[
i
o
t
[
v
a
f
ﬂ
i
e
a
Y
a
p
i
t
s
m
c
i
t
t
e
t
b
h
p
t
i
n
m
t
p
o
n
(
L
n
a
w
t
l
c
L
s246
Introduction
Some applications of gene therapy depend on high
gene transfer efﬁciencies into target tissues and
long-term expression of therapeutic transgenes.
Recombinant lentiviral vectors (LVs) have been
shown to be effective in transducing non- and/or
slowly dividing cells in vitro and in vivo, including
cardiac myocytes [1—4]. Our group has also shown
that direct injection of recombinant LVs into neona-
tal mice led to sustained systemic expression of
transgenes with wide distribution in many organs,
including the heart [5]. Thus, gene therapy using
direct injection of recombinant LVs seems to have
therapeutic potential for treatment of cardiac dis-
orders.
As an example in this context, Fabry disease
is the second-most prevalent lysosomal storage
disorder (LSD). Fabry disease is an X-linked reces-
sive disorder caused by a single gene defect for
a lysosomal hydrolase: -galactosidase A (-gal A,
EC 3.2.1.22) [6]. In Fabry disease, a reduction
in -gal A activity results in the accumulation of
galactosylsphingolipid moieties, especially globo-
triaosylceramide, which leads to cardiac [7] and
kidney [8] dysfunction. ‘Cardiac variant’ Fabry
disease has also been elucidated wherein manifes-
tations are only limited speciﬁcally to the heart
[9]. Enzyme replacement therapy using recombi-
nant enzyme has been available for Fabry disease
and can lead to improvement of some manifes-
tations [10—12]; however, this therapy requires
biweekly recombinant enzyme infusions throughout
life and the beneﬁt of this treatment may possi-
bly be affected by immune responses that have
been observed against the enzyme [10,11]. Most
problematic, however, is that enzyme replacement
therapy is started after the damage to most organs
may be irreversible. Therefore, earlier intervention
may be more effective than delayed treatment.
We have been developing oncoretroviral- [13—15]
and lentiviral-mediated gene therapy [16,17] for
Fabry disease including delivery to neonatal ani-
mals [5].
Regulation of vascular permeability is crucial for
organ function, since this barrier prevents transfer
of macromolecules, such as serum proteins, from
blood to tissues. However, disruption of the regula-
tory mechanism is often observed in many disease
conditions: acute inﬂammation, pathologies asso-
ciated with angiogenesis such as tumors, wounds,
ischemic diseases, and chronic inﬂammatory dis-
eases.
Vascular endothelial growth factor (VEGF) plays
a role in vasculogenesis, angiogenesis, and even
lymphangiogenesis [18,19]. Administration of VEGF
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nto neonatal animals enables increased trans-
ort of therapeutic proteins into the brain by
ncreasing the transient and reversible vascular
yperpermeability of the blood—brain barrier (BBB)
20]. It appears that VEGF enhances the activ-
ty of an organelle called the vesicular—vacuolar
rganelle that is found intermittently throughout
he endothelial cells (ECs) lining small blood vessels
21]. These organelles are clusters of vesicles and
acuoles that are interconnected with each other
nd the plasma membrane of the ECs by means of
enestrae that open and close to allow/prevent the
ow of macromolecules through the vesicles and
nto the tissue [22]. This characteristic has been
xploited by administering VEGF prior to gene ther-
py to increase gene transfer efﬁciency. Studies by
oung et al. using an authentic mouse model of
n LSD showed increased ingress of administered
rotein, bone marrow cells, or recombinant viruses
nto the central nervous system, along with greater
herapeutic levels of enzyme and increased life
pan in animals treated with VEGF compared to ani-
als preconditioned using irradiation or those not
onditioned [23]. In studies where LV was directly
njected, examination of the brain showed LV-
ransduced cells present in all areas of the brain and
ransduced cells included neurons, and glial and
ndothelial cells [23]. Neonatal gene transfer offers
he advantage of administering therapeutic vector
efore permanent organ and neurological damage
as occurred. It also offers the potential to tolerize
atients to the therapeutic protein expressed from
he vector since the immune system of neonates
s still relatively immature [24—26]. Thus, since
eonatal gene transfer combined with VEGF treat-
ent to increase distribution has the potential to
reat systemic manifestations early in life, it is a
romising therapeutic option for Fabry disease and
ther LSDs.
In the present study, a recombinant LV engi-
eering expression of luciferase in transduced cells
LV/luc) was used to track transgene expression.
V/luc was injected into the temporal vein of
eonatal mice, with or without addition of VEGF,
nd transgene expression was monitored over 12
eeks. Ex vivo imaging of the organs showed
hat VEGF pretreatment increased expression of
uciferase in the brain, lung, kidney, and heart
ompared to organs from the mice that received
V alone. These studies are the ﬁrst to demon-
trate that VEGF treatment prior to viral delivery
as a broad systemic effect in improving trans-
uction levels and provide encouraging evidence
hat this regimen can improve therapeutic out-
omes for a variety of disorders, including Fabry
isease.
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aterials and methods
V production and determination of titer
he lentiviral vector pHR’cppt-EF-luciferase
as previously been described [5]. VSV-g-
seudotyped LV/luc was produced by transient
o-transfection of 293T cells with LV/luc and
he accessory plasmids pMD.G and pCMVR8.91,
sing the polyethyleneimine-transfection proce-
ure [27—29]. Cell culture medium was changed
6 h post-transfection. Viral supernatants were
arvested after 48 h and concentrated by ultracen-
rifugation at 50,000× g for 2 h. The concentrated
irus was suspended in sterile phosphate buffered
aline (PBS) and stored at −80 ◦C until use. The
evel of p24 antigen in the LV/luc virus prepa-
ation was determined using an HIV-1 p24 ELISA
it (PerkinElmer Canada Inc., Vaudreuil-Dorian,
C, Canada) and was found to be ∼3100 ng
24/ml.
nimal procedures
he animal experimentation procedures described
erein were performed under protocols approved
y the University Health Network (UHN) Animal
are Committee. Balb/c mice were maintained at
he animal facility of the UHN. Two hours prior
o virus injection, 1.7 ng of recombinant mouse
EGF164 (R&D Systems, Minneapolis, MN, USA) was
dministered to 1—3-day-old neonatal mice through
he superﬁcial temporal vein in a volume of 100l.
ontrol mice received 100l of PBS. Concentrated
V (300 ng p24 in 100l PBS) was then injected via
he superﬁcial temporal vein.
n vivo and ex vivo bioluminescent imaging
n vivo bioluminescent imaging was performed
t the Advanced Optical Microscopy Facility at
he UHN with an IVIS Imaging System (Xenogen,
lameda, CA, USA), which comprised a cooled
harged coupled device (CCD) camera mounted
n a light-tight camera box. Images and measure-
ents of bioluminescent signals were acquired and
nalyzed using Living Image software (Xenogen).
or whole-body luminescence imaging, mice were
nesthetized, administered D-luciferin (Molecular
maging Products, Ann Arbor, MI, USA) at 100mg/kg
n PBS by intraperitoneal (i.p.) injection, and then
maged 10min later. For ex vivo organ imaging,
min after receiving D-luciferin, mice were killed
nd organs were collected and washed with PBS.
mages were then immediately acquired (5min
xposure time). Following imaging, the organs were
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ut in half. One half of each organ was immersed
n optimal cutting temperature (OCT) compound
Pelco International, Redding, CA, USA). The other
alf was transferred into a microcentrifuge tube,
rozen on dry ice, and then stored at −80 ◦C until
se.
mmunohistochemistry
ollowing ex vivo imaging, samples of each organ
ere cryopreserved in OCT compound and stored
t −80 ◦C. The specimens were cryosectioned to
5m thickness. The sections were mounted on
lass slides, air dried for 1 h at room temper-
ture, washed with PBS, and then post-ﬁxed in
% buffered formalin in 0.1M sodium phosphate
uffer, pH 7.4. Slides were washed with PBS and
hen incubated in PBS containing 0.1% (v/v) Tri-
on X-100 for 15min, the samples were treated
ith 5% (v/v) normal donkey serum in PBS for
0min. The sections were sequentially reacted with
rimary antibody solution (1:100 dilution in PBS)
t 4 ◦C overnight, followed by incubation in PBS-
ontaining secondary antibody (1:500 dilution in
BS) labeled with either Alexa488 or Alexa546 for
h at room temperature. Antibodies used in this
tudy were as follows: goat anti-luciferase anti-
ody (Chemicon International Inc., Temecula, CA,
SA), rat monoclonal anti-mouse CD31 antibody
BD Pharmingen, San Diego, CA, USA), rabbit anti-
ATA4 antibody (Santa Cruz Biotechnology, Inc.,
anta Cruz, CA, USA), rabbit anti-doublecortin
Abcam, Cambridge, MA, USA), rabbit anti-glial ﬁb-
illary acidic protein (GFAP) (Lab Vision, Fremont,
A, USA), Alexa488-labeled donkey anti-rabbit
r anti-rat IgG antibody (Molecular Probes, Inc.,
ugene, OR, USA), and Alexa546-labeled donkey
nti-goat IgG antibody (Molecular Probes). Fluo-
escence signals were analyzed using a confocal
aser-scanning microscope LSM-5 and LSM System
ersion 3.98 (Carl Zeiss, Oberkochen, Germany)
t the Common Instrument Center of Institute of
evelopment, Aging, and Cancer, Tohoku Univer-
ity.
easurement of organ luciferase activity
rgans were minced and homogenized using a
icrofuge pestle in 1× Cell Culture Lysis Reagent
Promega Corp., Madison, WI, USA). Lysates were
hen spun at 12,000× g for 5min at 4 ◦C. The
upernatants were transferred to a microcentrifuge
ube and luciferase activity was measured using
he Luciferase Assay System from Promega, as
er manufacturer’s instructions. Protein concen-
rations were measured using the Bio-Rad DC
248 T. Sato et al.
Figure 1 Whole-body luminescence imaging of mice showing long-term luciferase expression. One- to three-day-old
neonatal mice were injected with LV/luc in the absence (A) or the presence (B) of VEGF. VEGF was administered
2 h prior to the virus injection via the superﬁcial temporal vein. At 12 weeks post-virus delivery, mice were imaged
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representative mice from each group.
Protein Assay (Bio-Rad Laboratories, Mississauga,
ON, Canada) as per manufacturer’s instruc-
tions.
Statistical analysis
Data are presented as the mean± standard error
of mean (SEM). Statistical analyses were per-
formed using Instat version 3 software for Macintosh
(GraphPad, San Diego, CA, USA). Statistical analy-
sis was done using the Mann—Whitney test with the
level of signiﬁcance set at P < 0.05.
Results
Whole-body bioluminescence imaging
To determine the effect of VEGF administration on
the transduction pattern of LV on neonates in vivo,
1—3-day-old Balb/c mice were treated with VEGF
2 h prior to injection of LV/luc, whereas control
mice received the virus without VEGF pretreat-
ment. No adverse effects from VEGF pretreatment
were observed throughout the life of the animals.
Transgene expression in these immunocompetent
mice was detected by whole-body biolumines-
cence imaging (WBLI) following administration of
the D-luciferin substrate. It was found that the
luminescent signals generated by the luciferase
activity was detected from the mice in both groups
throughout the course of the experiment, begin-
ning at 4 weeks (data not shown) and persisting
at similar levels up to 12 weeks (Fig. 1). This
pattern is similar to that observed in our previ-
ous studies [5]. These results indicate that VEGF
administration is well tolerated and does not grossly
i
e
t
f
vluciferin from the dorsal side. Shown are images of four
ffect expression of the transgene as measured by
BLI.
EGF pretreatment increases luciferase
xpression in the heart and other organs
ollowing WBLI at week 12, mice were killed and
he organs were examined ex vivo by measuring
he luminescent signal intensity (Fig. 2A). The sig-
al intensity of the brain obtained from the mice
eceiving VEGF prior to injection of LV was greater
han that from VEGF (−) mice (Fig. 2B). It was
lso found that the lung, heart, and kidney from
EGF (+) mice showed increased signal intensity
ompared to organs from VEGF (−) mice, while
o apparent increases in signal were observed in
he liver and spleen (Fig. 2B). It should be noted
hat this might be due to the high level of the
uciferase expression in the liver and spleen that
ay have saturated the captured signal. Indeed,
hese organs appear to be the most readily pene-
rated and transduced by LV as seen in our previous
tudies [5].
eart tissue demonstrates the greatest
ncrease in luciferase activity with VEGF
retreatment
o determine the luciferase activity quantitatively
n each organ, specimens of each organ were
omogenized and the luciferase enzymatic activ-
ty in each sample was measured directly. As
xpected, direct luciferase activity of each of
he organs derived from LV/luc-treated mice was
ound to be 10—1000-fold higher compared to
alues from untreated mice (Fig. 3). VEGF pre-
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Figure 2 Ex vivo imaging of the luciferase expression in the organs at 12 weeks post-virus injection. Following whole-
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iody luminescence imaging, mice were killed and the o
rgans from representative mice from each group. (B) Th
he Living Image software. Values shown are means± SD.
reatment demonstrated a tendency to increase
he luciferase activity of each organ from 1.3-
o 6.6-fold compared to that without VEGF pre-
reatment. Importantly, the activity of the heart
as 6.6-fold higher in VEGF-treated mice com-
ared with that of VEGF-untreated mice (P < 0.05).
ncreased luciferase activity in the other organs
f VEGF-treated mice could not be demon-
trated by this assay. These ﬁndings are of
articular signiﬁcance for diseases that have mul-
iple organ involvement and especially important
or diseases with cardiac involvement such as
abry disease and some other metabolic disorders
30—32].
r
o
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a
(s were taken out and imaged. (A) Shown are images of
luminescent signal from each organ was measured using
8 per group, *P < 0.05).
mmunostaining of tissue sections to
dentify the transduced cells by LV/luc in
itu
ince the organ luciferase activity of the VEGF-
reated mice showed a dramatic increase compared
o that observed from the untreated mice, we next
xamined tissue sections by immunostaining to
dentify the speciﬁc type of cell that was producing
eporter enzyme. Tissue sections from the hearts
f transduced animals were immunostained using
n anti-luciferase antibody combined with either
n anti-CD31 antibody as a vascular EC marker
Fig. 4A) or an anti-GATA4 antibody as a myocardial
250
Figure 3 Comparison of the organ luciferase activity.
Organs were homogenized and the luciferase activity
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ences in the results obtained from the two methodswas measured using a luminometer. Values shown are
means± SEM (n = 8 for VEGF (−), n = 7 for VEGF (+), and
n = 4 for non-treated mice; *P < 0.05).
cell marker (Fig. 4B). It was found that both the
CD31-positive cells, namely, vascular ECs and the
GATA4-positive cells, namely, myocardial cells
showed the existence of immunoreactivity against
the anti-luciferase antibody in LV/luc-treated
mice, whereas only background levels of the ﬂu-
orescence signal from immunoreactive luciferase
was seen in untreated mice. These results suggest
that both the vascular ECs and the myocardial cells
themselves were transduced by LV/luc injection
into neonatal animals.
Tissue sections made from brains of infected
animals were also immunostained to identify the
type of cells transduced by LV/luc using either
an anti-doublecortin antibody as a neuronal cell
marker or an anti-GFAP antibody as a glial cell
marker. Immunoreactive luciferase in LV/luc mice
was detected in neuronal cells, including Purkinje
cells of the cerebellum as shown by staining with
an anti-doublecortin antibody (Fig. 4C), while no
immunoreactive luciferase could be detected in
glial cells in LV/luc mice (Fig. 4D). In the liver,
both the parenchymal and the vascular ECs showed
the presence of immunoreactive luciferase (data
not shown) in LV/luc-treated mice. These results
indicate that the systemically injected LV/luc trans-
duces not only the ECs but also the perivascular
cells in the brain.
Discussion
Angiogenesis is preceded and/or accompanied by
enhanced microvascular permeability. Regulation
of vascular permeability during angiogenesis is crit-
ical to normal and/or patho-physiological functions
and the families of proteins that appear to be
most important in regulating vascular permeabil-
o
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ty are the various members of the VEGF families
33]. For example, Young et al. found that admin-
stration of VEGF prior to injection of LV into
eonates disrupted the neonatal BBB and resulted
n increased numbers of cells transduced in the
rain [23]. While examination of other organs
n that study showed that VEGF had no overt
ffects on organ development and did not cause
umor development, there was no examination of
he effect on transgene expression speciﬁcally in
he organs themselves nor were the LV-transduced
ells identiﬁed in situ [23]. In the present study,
e have used a similar delivery approach using
uciferase as a marking transgene to determine
he effects of VEGF administration on the trans-
uction of the major internal organs. We found
hat the luciferase activity achieved in the hearts
f mice receiving both LV/luc and VEGF was sig-
iﬁcantly higher compared to those that did not
eceive VEGF (Fig. 3). Cellular localization analy-
is of the heart indicated that both the vascular
Cs and the myocardial cells were transduced
Fig. 4A and B).
Transgene expression in LV/luc-administered
ice was monitored monthly for 3 months by WBLI
nd it was found that the expression remained
teady in both VEGF (+) and VEGF (−) mice (Fig. 1).
uantiﬁcation of LV/luc expression by ex vivo
maging showed signiﬁcant increases of luciferase
ctivity in the heart, lung, and kidney of the
EGF-treated mice compared with those of the
EGF-untreated mice (Fig. 2B). The spleen and the
iver did not show signiﬁcant increases in trans-
ene expression mediated by the VEGF treatment
ut reporter gene expression in these organs was
igh in all mice treated with LV/luc. Indeed, we
ay have reached the saturation point of the assay,
nd as such, differences between groups would be
arder to detect. This ﬁnding is not surprising since
he liver is often the most highly transduced organ
hen virus is delivered directly into the blood-
tream [5,23,34].
The organ luciferase activity assays showed a sig-
iﬁcant increase in enzyme activity in the hearts of
EGF (+) mice while no signiﬁcant changes could be
etected in other organs (Fig. 3). Since gross sec-
ions were made for this assay, it is possible here
hat the enzyme was diluted in the background of
on-transduced tissue and that this had an impact
n the activity calculations in contrast to what was
bserved in the ex vivo imaging data. These differ-f analysis are likely caused by a number of fac-
ors including the architecture and vascularization
f the organ. Generation of luminescent signals
y luciferase requires molecular oxygen and sup-
VEGF increases LV distribution in heart 251
Figure 4 Identiﬁcation of the cell types that were transduced by LV/luc in the organs. Tissue sections were dually
immunostained with an anti-luciferase antibody (shown in red in each panel) and the speciﬁc marker of each tissue
(shown in green in each panel). Sections of the heart were counter-immunostained using either an antibody to (A)
vascular endothelial cell marker, CD31 or (B) myocardial cell marker, GATA4, respectively. Sections of the brains
were also counter-immunostained using either an antibody to (C) doublecortin or (D) GFAP, respectively. Images are
representative of sections from multiple mice in each group. In (C) and (D), the panels show only merged images. Bar:
100m.
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ply of the oxygen in each organ highly depends
on the vasculature of the tissue. Therefore, the
intensity and accuracy with which the lumines-
cent signal could be measured varied among the
organs. For instance, it was surprising that little
difference in organ luciferase activity was seen in
the lungs of VEGF (+) mice compared to that of
VEGF (−) mice since the macroscopic observation
obtained from the ex vivo imaging showed a larger
area of luminescence in the VEGF (+) mice than
in the VEGF (−) mice. However, the areas of the
lungs that were transduced by LV/luc in VEGF (−)
mice have a higher intensity signal than the areas
transduced in the VEGF (+) mice. These observa-
tions may be due to the highly vascularized nature
of the lung that allowed a more diffuse distri-
bution of the virus after administration of VEGF,
whereas in the VEGF (−) mice the virus appears
to have remained concentrated in a smaller area.
In the kidney, for example, only small concentrated
areas exhibiting luminescence were observed in the
VEGF (+) mice whereas no signiﬁcant difference in
organ luciferase activity between both groups was
observed. Since random sections were used for the
assay, the actual areas transduced by LV/luc may
have been inadvertently excluded from the analy-
ses.
Despite the differences in sensitivity of the two
methods of transgene detection used in this study,
it is clear that pre-administration of VEGF increases
d
a
a
vtinued ).
he efﬁciency of treatment with recombinant LVs.
he advantages of our experimental approach are:
1) increased persistence in key organs such as the
rain and heart; (2) more broad distribution; and (3)
arly intervention. This protocol has potential ther-
peutic beneﬁt for the treatment of diseases such
s mucopolysaccharidosis type I [35], polyglutamine
isorders [36], and other LSDs. Preliminary results
rom our immunohistochemical analyses show that
euronal cells of the brain and myocardial cells
n the heart are transduced by LV/luc and provide
vidence that the VEGF pretreatment enhances
he efﬁciency of gene transfer. Future studies will
nclude the staining of tissues from other organs
o determine the cell types transduced and the
attern of transduction in all organs. To deter-
ine the effect of VEGF on virus delivery to the
iver and spleen, similar studies should be per-
ormed using reduced amount of virus to allow
or the detection of differences between groups in
hese organs. In addition, testing in a relevant dis-
ase model such as Fabry mice will facilitate the
valuation of phenotypical correction and immuno-
ogical responses to the therapeutic enzyme. It
lso remains to be determined whether vascular
ermeability in humans at an analogous stage of
evelopment of the mouse is increased by the
dministration of VEGF and would as such, be
ffected in the same way by VEGF treatment and
iral administration.
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